To support myotonic dystrophy drug development efforts, MDF held a science workshop in September 2014 at our annual conference. The workshop brought together more than 50 DM researchers and industry representatives from around the world to review where we are in the development of clinical trial endpoint measures for DM.
Dr. Tetsuo Ashizawa, MD, has focused his career on the search for DM treatments and care for those affected. His multi-disciplinary, patient-centric approach to care moves DM research out of the lab and into his clinic at the University of Florida.
Dr. John Vissing and his colleagues at the University of Copenhagen recently tracked a group of 68 adults with myotonic dystrophy type 1 (DM1), measuring their endocrine function change over 8 years.
A comprehensive multidisciplinary DM clinic is scheduled to launch late 2014 at the University of Iowa Hospital providing easily accessable services for patients.
The DMCRN was established a little over three years ago to evaluate potential DM treatments, prepare possible clinical trial sites and conduct important DM research studies.